Landscape Capital Management L.L.C. purchased a new stake in shares of BridgeBio Pharma, Inc. (NASDAQ:BBIO – Free Report) in the 3rd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor purchased 9,197 shares of the company’s stock, valued at approximately $605,000.
Other hedge funds have also recently bought and sold shares of the company. Silvant Capital Management LLC acquired a new stake in BridgeBio Pharma during the second quarter worth approximately $28,000. Allworth Financial LP bought a new stake in shares of BridgeBio Pharma during the second quarter worth approximately $31,000. Root Financial Partners LLC bought a new stake in shares of BridgeBio Pharma during the third quarter worth approximately $28,000. SBI Securities Co. Ltd. grew its position in shares of BridgeBio Pharma by 55.3% in the third quarter. SBI Securities Co. Ltd. now owns 441 shares of the company’s stock valued at $29,000 after purchasing an additional 157 shares during the last quarter. Finally, Mitsubishi UFJ Asset Management Co. Ltd. acquired a new position in shares of BridgeBio Pharma in the second quarter valued at approximately $44,000. 99.85% of the stock is currently owned by institutional investors.
Wall Street Analysts Forecast Growth
Several analysts have recently issued reports on the company. Bank of America increased their target price on BridgeBio Pharma from $101.00 to $104.00 and gave the stock a “buy” rating in a report on Tuesday, August 11th. Barclays dropped their price target on BridgeBio Pharma from $157.00 to $156.00 and set an “overweight” rating for the company in a research note on Wednesday, October 7th. HC Wainwright reaffirmed a “buy” rating on shares of BridgeBio Pharma in a research report on Tuesday, October 6th. TD Cowen cut their price objective on shares of BridgeBio Pharma from $110.00 to $100.00 and set a “buy” rating for the company in a research report on Friday, October 30th. Finally, Morgan Stanley increased their price objective on shares of BridgeBio Pharma from $88.00 to $91.00 and gave the stock an “overweight” rating in a research note on Friday, November 13th. Nineteen investment analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat, the company currently has an average rating of “Moderate Buy” and an average price target of $104.42.
Get Our Latest Research Report on BBIO
Insider Buying and Selling at BridgeBio Pharma
In other news, CAO Maricel Apuli sold 2,000 shares of the business’s stock in a transaction that occurred on Friday, October 30th. The shares were sold at an average price of $72.85, for a total value of $145,700.00. Following the sale, the chief accounting officer owned 120,687 shares of the company’s stock, valued at $8,792,047.95. The trade was a 1.63% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CEO Neil Kumar sold 10,000 shares of the stock in a transaction dated Wednesday, November 18th. The stock was sold at an average price of $77.72, for a total transaction of $777,200.00. Following the completion of the sale, the chief executive officer directly owned 485,686 shares in the company, valued at approximately $37,747,515.92. The trade was a 2.02% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last 90 days, insiders sold 56,980 shares of company stock worth $4,332,346. Corporate insiders own 14.23% of the company’s stock.
BridgeBio Pharma Price Performance
Shares of NASDAQ:BBIO opened at $76.03 on Friday. The business’s 50-day moving average is $70.30 and its 200-day moving average is $72.77. BridgeBio Pharma, Inc. has a 1 year low of $62.50 and a 1 year high of $93.42.
BridgeBio Pharma (NASDAQ:BBIO – Get Free Report) last announced its quarterly earnings data on Thursday, October 29th. The company reported ($0.42) EPS for the quarter, beating analysts’ consensus estimates of ($0.54) by $0.12. The firm had revenue of $353.17 million during the quarter, compared to analyst estimates of $293.47 million. During the same period last year, the business posted ($0.95) EPS. The company’s revenue was up 192.6% on a year-over-year basis. Equities analysts anticipate that BridgeBio Pharma, Inc. will post -2.55 EPS for the current fiscal year.
About BridgeBio Pharma
BridgeBio Pharma is a biopharmaceutical company that discovers, develops and commercializes medicines for genetic diseases and cancers. Founded in 2015, the company advances programs through a network of research and development subsidiaries focused on specific conditions and therapeutic areas. Its products include Attruby (acoramidis), an FDA-approved treatment for adults with transthyretin amyloid cardiomyopathy. BridgeBio also develops a pipeline of investigational therapies aimed at diseases with well-understood genetic causes, including rare and inherited conditions.
See Also
- Five stocks we like better than BridgeBio Pharma
- MarketBeat Week in Review – 11/16 – 11/20
- Survey Reveals: How Much Would People Pay for Ribeye Before Giving It Up? [2026]
- If NVIDIA Tightens Its Wallet, These 3 Stocks Could Feel It
- 3 Dividend ETFs Offering Steadier Footing in a Shaky Market
Want to see what other hedge funds are holding BBIO? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for BridgeBio Pharma, Inc. (NASDAQ:BBIO – Free Report).
Receive News & Ratings for BridgeBio Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BridgeBio Pharma and related companies with MarketBeat.com's FREE daily email newsletter.
